Microcide Pharmaceuticals (MCDE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Microcide Pharmaceuticals (MCDE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Metcalf who wrote (110)	8/29/1997 12:19:00 AM
From: Dave K	of 186

I do recall someone mention the Camden NJ incident but have not see an official release on this. This raises a question as to how resistance is actually monitored globally. Is it conceivable that the baterial resistance could go unreported in many cases. On another issue: Any thoughts on what the expanded use of antibiotics for other conditions (below) may do to the resistance. I have not been able to research roxithromycin as my regular ISP has gone down the drain tonight. What's it typically used for ? ================= Studies have shown that infection with C. pneumoniae, when exacerbated by factors such as smoking and poor general health, can precipitate physiological changes that may lead to heart attack. According to Professor Saikku and Dr. Leinonen, eliminating C. pneumoniae infection could lower the incidence of heart disease. Preliminary results from current research have shown that heart disease patients who test positive to C. pneumoniae infection and are treated with antibiotics, such as roxithromycin, have a reduced risk of heart attack. Chlamydia pneumoniae has also been linked to the development of asthma in some patients. Associate Professor Francesco Blasi, of the Institute of Respiratory Diseases at the University of Milan is a leading investigator in an international study researching the link between C. pneumoniae and asthma and the effect of treating asthmatic patients with the antibiotic roxithromycin. =============== Also found this. Can someone possibly find JAMA issue and post it ? Vancomycin-Resistant Enterococcus faecium (VREF) the rise of vancomycin-resistant Enterococcus faecium (VREF) infections has proven increasingly challenging to physicians in selecting appropriate antibiotics(1). (1) Tenover, Fred C. The challenges of emerging infectious diseases: Development and spread of multiply-resistant bacterial pathogens. JAMA. 1996 275 300-304.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next